Understanding and treating developmental brain disorders
Since the failure of phase 3 (bumetanide to treat autism), we have stopped all experimental (animal) research. Our focus now is on the identification of bumetanide responder children to foster more adequate clinical trials.
Neurochlore also invests in B&A Oncomedical and B&A Biomedical to respectively treat tumors and use Machine Learning to identify at birth babies who will be diagnosed later with autism.
News
Although the phase III clinical trial was a failure, Neurochlore was able to retrieve data that could be promising. …
IBEN will give a satellite conference at the FENS 2022, an european congress of neurosciences.
The conference, which take place …
Past research
Our research aims at determining brain development alterations that lead to Autism Spectrum Disorders (ASD) and other Neurodevelopmental Disorders and identifying therapeutic targets.